Inactivation of the Enzyme GSK3α by the Kinase IKKi Promotes AKT-mTOR Signaling Pathway that Mediates Interleukin-1-Induced Th17 Cell Maintenance  by Gulen, Muhammet F. et al.
Immunity
ArticleInactivation of the Enzyme GSK3a by the Kinase IKKi
PromotesAKT-mTORSignalingPathwaythatMediates
Interleukin-1-InducedTh17CellMaintenance
Muhammet F. Gulen,1 Katarzyna Bulek,1 Hui Xiao,4 Minjia Yu,1 Ji Gao,5 Lillian Sun,6 Eleonore Beurel,7
Oksana Kaidanovich-Beilin,8 Paul L. Fox,2 Paul E. DiCorleto,2 Jian-an Wang,9 Jun Qin,3 David N. Wald,6
James R. Woodgett,8,10 Richard S. Jope,7 Julie Carman,5 Ashok Dongre,5 and Xiaoxia Li1,*
1Department of Immunology, Lerner Research Institute
2Department of Cell Biology, Lerner Research Institute and Cleveland Clinic Lerner College of Medicine
3Department of Molecular Cardiology, Lerner Research Institute
Cleveland Clinic Foundation, Cleveland, OH 44195, USA
4Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Shanghai 200025, China
5Discovery Biology, Bristol-Myers Squibb, Princeton, NJ 08543, USA
6Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
7Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL 33136, USA
8Samuel Lunenfeld Research Institute at Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada
9Department of Molecular Cardiology, Second Affiliated Hospital, Scholl of Medicine, Zhejiang University, Hangzou 310009, China
10Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2M9, Canada
*Correspondence: lix@ccf.org
http://dx.doi.org/10.1016/j.immuni.2012.08.019SUMMARY
Interleukin-1 (IL-1)-induced activation of the mTOR
kinase pathway has major influences on Th17 cell
survival, proliferation, and effector function. Via bio-
chemical and genetic approaches, the kinases IKKi
and GSK3a were identified as the critical interme-
diate signaling components for IL-1-induced AKT
activation, which in turn activated mTOR. Although
insulin-induced AKT activation is known to phos-
phorylate and inactivate GSK3a and GSK3b, we
found that GSK3a but not GSK3b formed a constitu-
tive complex to phosphorylate and suppress AKT
activation, showing that a reverse action from GSK
to AKT can take place. Upon IL-1 stimulation, IKKi
was activated to mediate GSK3a phosphorylation
at S21, thereby inactivating GSK3a to promote
IL-1-induced AKT-mTOR activation. Thus, IKKi
has a critical role in Th17 cell maintenance and/or
proliferation through the GSK-AKT-mTOR pathway,
implicating the potential of IKKi as a therapeutic
target.
INTRODUCTION
Invading pathogens are detected by the innate immune system
through the recognition of pathogen-associated molecular
patterns by various pattern recognition receptors including
Toll-like receptors. The activation of pattern recognition recep-
tors induces the production of inflammatory cytokines such as
IL-1 and TNF, leading to inflammatory responses (Kawai and
Akira, 2007). Activation of professional antigen-presenting800 Immunity 37, 800–812, November 16, 2012 ª2012 Elsevier Inc.cells through the pattern recognition receptors leads to the
onset of adaptive immunity, triggering the differentiation and
activation of CD4+ T helper (Th) lymphocytes, which is essential
in regulating immune responses and autoimmune and inflam-
matory diseases (Janeway and Medzhitov, 2002). Th17 cells
have been defined as a distinct lineage of CD4+ Th cells that
produce IL-17, IL-17F, IL-21, and IL-22 (Langrish et al., 2005;
Bettelli et al., 2006; Harrington et al., 2005; Mangan et al.,
2006; Park et al., 2005; Veldhoen et al., 2006). Th17 cells
have attracted tremendous attention in immunology as a result
of their important function in host defense against bacterial
and fungal infection and potent pathogenic role in autoimmune
and inflammatory diseases (Langrish et al., 2005; Park et al.,
2005).
Several cytokines including TGF-b and IL-6 are required
for Th17 cell differentiation upon T cell receptor (TCR) acti-
vation. Transcription factors including STAT3 together with
lineage-specific factors RORa and RORgt direct Th17 cell
development and effector function through induction of a
set of signature cytokines and cytokine receptors, including
IL-23R and IL-1R (Korn et al., 2009; Wei et al., 2007; Ivanov
et al., 2006; McGeachy et al., 2007). Although the detailed
molecular mechanism is still unclear, mice lacking either
IL-1 or IL-23 are resistant to disease induction in Th17
cell-dependent collagen-induced arthritis (CIA), experimental
autoimmune encephalomyelitis (EAE), and inflammatory
bowel disease (IBD) (Ben-Sasson et al., 2009; Sutton et al.,
2006; Murphy et al., 2003; Langrish et al., 2005; Chung et al.,
2009).
Although the detailed molecular mechanism is still unclear,
IL-1 has major influences on Th17 cell development and
effector function, possibly through cell proliferation and survival
to maintain the differentiated state of Th17 cells (Korn et al.,
2009; Gulen et al., 2010). IL-1 stimulation leads to strong and
prolonged activation of the mammalian target of rapamycin
Figure 1. PI3K and AKT Are Required for
IL-1-Induced mTOR Activation
(A) Cell lysates from wild-type and Irak4/ Th17
cells untreated or treated with IL-1 (10 ng/ml) for
different time points were analyzed by protein blot
analysis with antibodies as indicated.
(B and C) Wild-type Th17 cells were untreated
or treated with IL-1 (10 ng/ml) for different
time points in the presence and absence of
10 mM PI3K inhibitor (LY294002) (B) and 1 mM
AKT inhibitor (AKT IV) (C). Cell lysates were
analyzed by protein blot analysis with antibodies
as indicated.
(D) Wild-type Th17 cells were rested overnight,
followed by incubation with 10 ng/ml IL-1 in the
presence and absence of 10 mM PI3K inhibitor
(LY294002). The treated cells were incubated 1
additional day with 3H for thymidine incorporation
experiment. Error bars, SD; **p < 0.01 (two-tailed
t test). Data are representative of three indepen-
dent experiments.
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IL-1-Induced IKKi Modulate GSK3a for mTOR Activity(mTOR) pathway in Th17 cells, including phosphorylation of
mTOR and downstream components 4E-BP1 and S6, which
play a key role in controlling protein translation. 4E-BP1 is
a repressor for protein translation through its interaction with
translation initiation factor eIF4E. Phosphorylation of 4E-BP1
by mTOR disrupts its interaction with eIF4E, thereby promoting
protein translation, especially on mRNAs with structured 50 UTR
including cMyc and Cyclin D1 (Hashemolhosseini et al., 1998;
Nelsen et al., 2003). Although mTOR signaling is known to
have a major impact on cell growth and proliferation, the
mTOR inhibitor rapamycin abolishes IL-1-induced cell prolifer-
ation in Th17 cells, indicating the importance of IL-1-induced
mTOR activation in IL-1-dependent Th17 cell maintenance
and/or proliferation.
We investigated the intermediate signaling events for IL-1-
induced mTOR activation and how this pathway is modulated.
We found that AKT was sequestered in a complex with
IKKi and glycogen synthase kinase 3a (GSK3a) before IL-1
stimulation. GSK3a negatively regulates AKT activation by
phosphorylating AKT at T312 in the substrate binding site,
which inhibited IL-1-induced AKT activation and function.
Importantly, although IKKi constitutively interacted with
GSK3a, IL-1 stimulation induced the recruitment of IKKi to
the TRAF6-TAK1 signaling complex. IKKi (also known as
IKKε or I kappaB kinase ε) is then activated to mediate IL-1-
induced GSK3a phosphorylation at S21 and consequent
inactivation of GSK3a, resulting in AKT-mTOR activation. It is
important to note that whereas PI3K and AKT are known toImmunity 37, 800–812, Nbe upstream kinases for insulin-induced
GSK3 phosphorylation and inactivation,
this study provides an example that
a reverse action from GSK to AKT
can take place. We also demonstrate
a distinct role of GSK3a versus GSK3b
in IL-1 signaling, implicating the spe-
cific function of GSK3a in autoim-
mune inflammatory responses. The IL-1-induced IKKi-GSK3a-mediated AKT-mTOR axis is probably
not only critical for the modulation of Th17 cell proliferation
and Th17 cell-dependent autoimmunity, but also is important
for coordinated regulation of immune responses and cell
metabolism.
RESULTS
PI3K and AKT Are Required for IL-1-Induced
mTOR-Dependent Th17 Cell Proliferation
PI3K and AKT are upstream positive regulators of mTOR
through the phosphorylation of TSC2 and consequent disrup-
tion of TSC1/TSC2 heterodimer (Manning et al., 2002; Inoki
et al., 2002). IL-1 stimulation indeed induced AKT (T308 and
S473) and TSC2 (T1462) phosphorylation in wild-type Th17
cells, which was abolished in IRAK4-deficient Th17 cells (Fig-
ure 1A). To test the necessity of PI3K activity in IL-1-induced
mTOR activation, Th17 cells were stimulated with IL-1 in the
presence or absence of PI3K (LY294002) and AKT (AKTIV)
inhibitors. LY294002 and AKTIV effectively inhibited IL-1-
induced phosphorylation of mTOR and downstream compo-
nents p70S6K, S6, and 4EBP1 (Figures 1B and 1C), whereas
phosphorylation of the kinases IқBa and p38 was not affected.
Furthermore, IL-1-induced survival and/or proliferation of
Th17 cells was also substantially reduced in the presence
of LY294002 (Figure 1D), indicating the requirement of the
PI3K-AKT axis in IL-1-mediated mTOR activation and Th17
cell maintenance and/or proliferation.ovember 16, 2012 ª2012 Elsevier Inc. 801
Figure 2. IL-1R-Mediated GSK3a Phos-
phorylation Is Independent on PI3K-AKT
Kinase Activity
(A) Lysates from 293-IL-1R cells untreated or
treated for 15 or 30 min with IL-1 (1 ng/ml) were
immunoprecipitated with anti-AKT, anti-GSK3a,
and anti-GSK3b, followed by protein blot analysis.
WCL, whole cell lysates.
(B) GSK3a was pulled down with two rounds of
immunoprecipitation. Immunoprecipitated com-
plex, whole cell lysate, and the remaining super-
natant were analyzed by protein blot analysis with
GSK3a and AKT1 antibody.
(C) Wild-type Th17 cells were untreated or treated
with IL-1 (10 ng/ml) for different time points in the
presence and absence of 1 mM AKT inhibitor (AKT
IV). Cell lysates were analyzed by protein blot
analysis with antibodies as indicated. Densitom-
etry quantitation of pooled data is plotted below.
(D) Wild-type bone marrow macrophages were
untreated or treated with insulin (10 nM) for
different time points in the presence and absence
of 1 mM AKT inhibitor (AKT IV). Cell lysates were
analyzed by protein blot analysis with antibodies
as indicated.
(E) Cell lysates from wild-type and Gsk3a/ Th17
cells untreated or treated with IL-1 (10 ng/ml) for
different time points were analyzed by protein blot
analysis with antibodies as indicated.
(F) Wild-type andGsk3a/ Th17 cells were rested
overnight, followed by incubation with 10 ng/ml
IL-1 or IL-2 for 3 additional days and with 3H for 1
more day for thymidine incorporation experiment.
(G) Naive wild-type, Gsk3a/ CD4+ T cells
(CD4+CD44lo) were polarized to Th17 cells in
the presence and absence of IL-1b, followed
by intracellular cytokine staining for IL-17 and
IFN-g.
(H) Real-time PCR analysis of relative expression
of IL-17, IL-21, IL-23R, and RORgt in wild-type
and Gsk3a/ Th17 cells as compared to the Th0
cells.
Error bars in (F)–(H) indicate SD; **p < 0.01 (two-
tailed t test). All data are representative of three
independent experiments.
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of PI3K-AKT Kinase Activity
To identify intermediate signaling components that mediate
IL-1-induced AKT activation, we searched for AKT-interacting
proteins. Coimmunoprecipitation of lysates from 293 cells trans-
fected with IL-1R (293-IL-1R) showed that AKT interacted with
GSK3a, but not GSK3b (Figure 2A). IL-1 stimulation further
induced the interaction of AKT with GSK3a. GSK3a and
GSK3b were not coimmunoprecipated, suggesting that they
are probably not in the same complex (Figure 2A). Furthermore,
when GSK3a was depleted in the supernatant after two cycles
of immunoprecipitation, there was still a substantial amount of
AKT in the supernatant, implying that GSK3a-AKT represents
one of the AKT complexes in the cells (Figure 2B). The activated
AKT upon insulin stimulation are known to phosphorylate
GSK3a (S21) and GSK3b (S9), inactivating GSK3 activity, which
then removes its inhibitory effect on glycogen synthase (Cross
et al., 1995). IL-1 stimulation also induced phosphorylation of
GSK3a (S21) and GSK3b (S9) in wild-type Th17 cells, which802 Immunity 37, 800–812, November 16, 2012 ª2012 Elsevier Inc.was abolished in IRAK4-deficient cells (Figure S1 available
online). Whereas PI3K and AKT inhibitors completely blocked
insulin-induced GSK3a and GSK3b phosphorylation, both inhib-
itors partially attenuated IL-1-induced GSK3b but not GSK3a
phosphorylation (Figures 2C, 2D, and S2A). The inhibition of
AKTIV on IL-1-induced GSK3b phosphorylation is consistent
with the previous finding that AKT mediates GSK3b phospho-
rylation to remove the inhibitory effect of GSK3b on mTOR acti-
vation (Cross et al., 1995). In contrast, these results indicate
differential roles of GSK3a and GSK3b in IL-1 signaling.
GSK3a Negatively Modulates IL-1-Induced
AKT-mTOR Activity
An important question was then whether and how GSK3a
contributes to IL-1-dependent effector function in Th17 cells.
We first examined the impact of GSK3a deficiency on IL-1-
mediated signaling in Th17 cells. Whereas p38 phosphorylation
was not affected, both constitutive and IL-1-induced AKT-
mTOR activation (phosphorylation of AKT, mTOR, p70S6K,
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IL-1-Induced IKKi Modulate GSK3a for mTOR Activityand S6) were substantially enhanced in GSK3a-deficient Th17
cells compared to that in wild-type cells (Figures 2E and S2B).
Consistent with the increased mTOR activity, GSK3a deficiency
resulted in enhanced IL-1-mediated Th17 cell maintenance
and/or proliferation (Figure 2F). GSK3a did not have much
impact on the response of Th17 cells to IL-2, indicating the
specific function of this component in the IL-1 pathway (Fig-
ure 2F). WT and Gsk3a/ naive T cells were differentiated into
Th17 cells with or without IL-1b stimulation. Similar numbers of
IL-17-positive cells (10%–12%) were detected in WT and
Gsk3a/ T cells under TGF-b+IL-6-mediated differentiation
condition (in the absence of IL-1b stimulation) (Figure 2G). Impor-
tantly, although IL-1b promoted Th17 cell differentiation in both
WT and Gsk3a/ T cells, addition of IL-1b resulted in a signifi-
cantly higher IL-17-positive population in Gsk3a/ T cells than
that in WT T cells (Figure 2G). Consistent with flow cytometry
analysis, the expression of other Th17 cell-associatedmolecules
(including IL-17, RORgt IL-21, and IL-23R) was also much higher
in Gsk3a/ T cells than that in WT cells in the presence of IL-1b
stimulation (Figure 2H). Taken together, these results suggest
that GSK3a actually negatively regulates IL-1-induced AKT-
mTOR activity and consequently suppresses IL-1-dependent
Th17 cell differentiation and survival/proliferation. The fact that
IL-1 induces specific interaction of GSK3a with PI3K and AKT
(Figure 2A) suggests that GSK3a might act upstream of PI3K
and AKT and modulate their activity in response to IL-1 stimu-
lation, which is consistent with the observation that GSK3a
phosphorylation was not inhibited by PI3K and AKT inhibitors
(Figure 2C). Importantly, whereas IL-1 stimulation led to
increased AKT and S6 phosphorylation in Gsk3a/ MEFs, the
insulin-induced AKT and S6 phosphorylation was comparable
in wild-type and Gsk3a/ MEFs (Figure S2C). These results
support the notion that GSK3a has an inhibitory role in IL-1-
induced but not insulin-induced AKT activation.
GSK3a Phosphorylates AKT and Inhibits
Its Kinase Activity
We then explored how GSK3a inhibits IL-1-induced AKT-mTOR
activation. Through coimmunoprecipitation of lysates from
293-IL-1R cells with anti-GSK3a or anti-GSK3b followed by
in vitro kinase assay, it was noted that GSK3a, but not GSK3b,
immunoprecipitates phosphorylated a protein at the size of
AKT (Figure 3A). These results are consistent with the observa-
tion that AKT was coimmunoprecipiated only with GSK3a, not
with GSK3b (Figure 2A). In vitro kinase assay with recombinant
proteins showed that GSK3a indeed promoted AKT phosphory-
lation (Figure 3B). Tandem MS revealed that GSK3a promoted
AKT phosphorylation at T312 (Figure 3C). Figure S3 showed
the structure of active AKT kinase domain (green) bound to
the substrate GSK3b peptide (cyan). Phosphorylation of the
activation loop at T308 (blue with phosphate group in red) is
essential for AKT activation. T312 (yellow) of AKT is in the
substrate binding site and the phosphorylation on its side chain
hydroxyl group (red) will cause steric clash with the substrate,
thereby inhibiting the AKT kinase activity. To assess the impact
of phosphorylation of T312 on AKT activation and function, we
mutated T312 to aspartic acid (D) to mimic phosphorylation
and transfected empty vector, flag-tagged wild-type, and AKT
mutant (AKTT312D) into 293-IL-1R cells. The cell lysates fromIthe transfected cells were immunoprecipitated with anti-flag
(M2) to pull down wild-type and mutant AKT, followed by
in vitro kinase assay with recombinant GSK3b as a substrate.
As shown in Figure 3D, AKTT312D displayed attenuated kinase
activity compared to wild-type AKT, demonstrating that
GSK3a-mediated phosphorylation of T312 is inhibitory for AKT
activation and function.
IL-1 Induces IKKi Activation to Mediate GSK3a
Phosphorylation
Because IL-1-induced GSK3a phosphorylation was not inhibited
by PI3K and AKT inhibitors, a different kinase probably functions
upstream of GSK3a and is responsible for the phosphorylation
of GSK3a in response to IL-1 stimulation. Through coimmuno-
precipitation of lysates from 293-IL-1R cells, we found that
GSK3a, but not GSK3b, formed a complex with IKKi (Figure 4A).
Importantly, whereas IkBa phosphorylation was intact, IL-1-
induced GSK3a and GSK3b phosphorylation was greatly
reduced in IKKi-deficient Th17 cells compared to that in wild-
type cells (Figure 4B), implying that IKKi might be the upstream
kinase of GSK3 in response to IL-1 stimulation.
Upon IL-1 stimulation, adaptor MyD88 is recruited to the IL-1
receptor, followed by the recruitment of serine and threonine
kinases IRAKs (interleukin-1 receptor-associated kinases) and
TRAF6. IRAK4 mediates the phosphorylation of IRAK1 and
IRAK2, followed by the activation of TAK1 and IKK in a TRAF6-
dependent manner, leading to NF-kB activation (Yao et al.,
2007). Interestingly, we found that the IL-1 stimulation induced
the interaction of TRAF6-TAK1 with the IKKi-GSK3a complex
in 293-IL-1R cells (Figure 4C). Because IKKi is important in
IL-1-induced GSK3 phosphorylation, we examined IL-1-medi-
ated IKKi activation. We immunoprecipitated IKKi from cell
lysates of MEFs and primary kidney epithelial cells untreated
and treated with IL-1, followed by in vitro kinase assay.
Increased IKKi phosphorylation was detected in lysates from
both cell types 10–15 min after IL-1 stimulation (Figure 4D),
demonstrating IL-1-induced IKKi activation in cell culture model.
IL-1-induced IKKi autophosphorylation was substantially
reduced in IRAK4-deficient kidney epithelial cells and TRAF6-
and TAK1-deficient MEFs. These results indicate that IL-1
stimulation specifically leads to IKKi activation in an IRAK4-
TRAF6-TAK1-dependent manner. We then examined whether
IKKi can directly phosphorylate GSK3 in vitro. Both GSK3a
and GSK3b immunoprecipitated from 293-IL-1R cells were
subjected to in vitro kinase assay with or without recombinant
IKKi protein. Importantly, we observed that recombinant IKKi
was able to effectively phosphorylate GSK3a but not GSK3b
in vitro (Figure 4E). Thus, IKKi directly phosphorylates only
GSK3a, whereas the impact of IKKi on IL-1-induced GSK3b
phosphorylation is likely to be indirect, probably through the
activation of an intermediate kinase(s). In support of this,
recombinant IKKi was also able to phosphorylate only recom-
binant GSK3a but not GSK3b in an in vitro kinase assay, indi-
cating that IKKi is a direct upstream kinase of GSK3a (Figure 4F).
IKKi-Mediated Inactivation of GSK3a Is Required
for IL-1-Induced AKT-mTOR Activation
We next attempted to identify the IKKi-mediated phosphoryla-
tion sites of GSK3a by tandem mass spectrometry. A GSK3ammunity 37, 800–812, November 16, 2012 ª2012 Elsevier Inc. 803
Figure 3. GSK3a Phosphorylates and Inhibits AKT
(A) Lysates from 293-IL-1R cells untreated or treated for 15 or 30 min with IL-1 (1 ng/ml) were immunoprecipitated with anti-GSK3a and anti-GSK3b, followed by
in vitro kinase reaction in the presence (first lane) or absence of recombinant AKT.
(B) Recombinant AKT and GSK3a proteins were incubated in kinase reaction in the presence and absence of GSK3 inhibitor (30 mM SB415286).
(C) Tandem mass spectrometry (ms2) of precursor ions in the AKT1 phosphopeptide (amino acids 308–328; sequence TFCGpTPEYLAPEVLEDNDYGR).
(D) 293-IL-1R cells were transfected with flag-tagged wild-type AKT1, T312D mutant AKT1, or empty vectors. The cell lysates from the transfected cells were
immunoprecipitated with anti-flag antibody (M2), followed in vitro kinase assay with recombinant GSK3b as a substrate.
Data are representative of at least three separate experiments.
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SASGPGGTGGGK) was phosphorylated on S21 (Figure 4G).
Previous studies have shown that phosphorylation of S21 results
in theN-terminal domain of GSK3a interacting with its phosphate
binding pocket, preventing recognition of primed substrates
(Frame et al., 2001). Therefore, it is possible that IKKi-mediated
GSK3a phosphorylation at S21 also attenuates GSK3a kinase804 Immunity 37, 800–812, November 16, 2012 ª2012 Elsevier Inc.activity, thereby removing the inhibitory effect of GSK3a on
IL-1-induced AKT-mTOR activity. To test this hypothesis, we
employed GSK3a knockin mice in which S21 was mutated to
alanine. Whereas IL-1-induced p38 phosphorylation was intact,
AKT (T308 and S473)-mTOR activation was substantially
deceased in Gsk3a21A/21A Th17 cells as compared to that in
wild-type cells (Figure 5A). Consistent with the decreased
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was reduced in Gsk3a21A/21A Th17 cells as compared to that
in wild-type cells (Figure 5B). WT and Gsk3a21A/21A naive
T cells were differentiated into Th17 cells with or without IL-1b
stimulation. Similar numbers of IL-17-positive cells were de-
tected in WT and Gsk3a21A/21A T cells under TGF-b+IL-6-medi-
ated differentiation condition (in the absence of IL-1b stimulation)
(Figure 5C). Importantly, although IL-1b promoted Th17 cell
differentiation in both WT and Gsk3a21A/21A T cells, addition of
IL-1b resulted in a significantly reduced IL-17-positive popula-
tion in Gsk3a21A/21A T cells than that in WT T cells (Figure 5C).
Furthermore, the expression of Th17 cell-associated molecules
(including RORgt, IL-17, IL-21, and IL-23R) was also much
lower inGsk3a21A/21A T cells than that in WT cells in the presence
of IL-1b stimulation (Figure 5D). Thus, IKKi-mediated GSK3a
phosphorylation at S21 is indeed required for the inactivation
of GSK3a to remove GSK3a’s inhibitory effect on AKT, which
is critical for IL-1-induced activation AKT-mTOR and Th17 cell
maintenance and/or proliferation.
IKKi Deficiency Leads to Loss of IL-1-Induced
AKT-mTOR Activation
We examined the direct impact of IKKi deficiency on IL-1-medi-
ated AKT-mTOR pathway and IL-1-dependent Th17 cell mainte-
nance and/or proliferation. IL-1-induced phosphorylation of AKT
(T308), TSC2, mTOR, and downstream components p70S6K,
S6, and 4EBP1 were markedly reduced in IKKi-deficient Th17
cells compared to that in wild-type cells (Figure 6A). Consistent
with the decreased AKT-mTOR activation, IKKi deficiency
substantially reduced IL-1-mediated impact on Th17 cell mainte-
nance and/or proliferation compared to that in wild-type cells
(Figure 6B). However, IKKi deficiency did not have much impact
on the response of Th17 cells to IL-2, indicating the specific
function of IKKi in IL-1 pathway (Figure 6B). Although IKKi defi-
ciency did not have much impact on TGF-b+IL-6-mediated
Th17 cell differentiation, addition of IL-1b resulted in a markedly
reduced IL-17-positive population in Ikbke/ T cells than that
in WT T cells (Figure 6C). Furthermore, the expression of Th17
cell-associated molecules (including RORgt, IL-17, IL-21, and
IL-23R) was also much lower in Ikbke/ T cells than that in
WT cells in the presence of IL-1b stimulation (Figure 6D). These
results suggest that IKKi not only functions as an upstream
kinase of GSK3a but also plays a critical role in IL-1-induced
AKT-mTOR activation in Th17 cells and consequent Th17 cell
maintenance and/or proliferation (Figure S5).
An important question is how is AKT activated upon IL-1 stim-
ulation. IKKi can directly mediate AKT phosphorylation and
activation in response to EGF stimulation (Xie et al., 2011; Guo
et al., 2011). Because IKKi is required for IL-1-induced activa-
tion of AKT-mTOR signaling pathway, we examined a possible
direct role of IKKi in IL-1-mediated AKT activation. Through
coimmunoprecipitation, we found that IKKi forms a complex
with AKT (data not shown). Furthermore, we observed that
recombinant IKKi was able to effectively phosphorylate AKT
in vitro (Figure 6E), indicating that IKKi probably is able to directly
phosphorylate AKT.
Because PI3K signaling is required for IL-1-induced AKT-
mTOR activation (Figures 1B and 1D), we wondered whether
PDK1 might also be involved in IL-1-induced AKT phosphory-Ilation and activation. We found that IL-1-induced PDK1 phos-
phorylation was detected in both wild-type and IKKi-deficient
Th17 cells, indicating that PDK1 activation is IKKi independent
(Figure 6A). Although IKKi can directly phosphorylate AKT, it is
unclear whether PDK1 is also required for IL-1-induced AKT
activation. We found that IL-1-induced GSK3, JNK, and
IkBa phosphorylations were intact in PDK1-deficient colon
cancer cells, whereas IL-1-induced phosphorylation of AKT
T308 and downstream components of mTOR (p70S6K, S6,
and 4EBP1) were abolished in the absence of PDK1 (Fig-
ure 6F). PDK1 deficiency did not have much impact on IL-1-
induced AKT phosphoryaltion at S473 (Figure 6F), which
might be directly phosphorylated by IKKi (Xie et al., 2011;
Guo et al., 2011).
The Impact of IKKi and GSK3a on Th17 Cell Effector
Function in Induction of EAE
IL-1-mediated signaling in T cells is essential for in vivo Th17
cell differentiation and IL-17-dependent autoimmune diseases
(Sutton et al., 2006). Here we showed that IKKi functions down-
stream of IRAK4 to mediate IL-1-induced AKT-mTOR activation
and ex vivo Th17 cell survival and/or proliferation. To determine
the importance of IKKi on IL-1-mediated impact on Th17 cells
in vivo, we transferred MOG-specific Th17 cells from the WT
and Ikbke/ mice to sublethally irradiated Il1r/ mice, fol-
lowed by 7 days of injection of either PBS or IL-1b. Whereas
IL-1b treatment induced IL-17-producing MOG-specific
T cells in Il1r/ mice, IKKi deficiency reduced the impact of
IL-1 on MOG-specific Th17 cells (Figure 7A). The functionality
of MOG-specific Th17 cells from the WT and Ikbke/ mice
was also compared by adoptive transfer to WT recipient
mice. Compared to MOG35-55-specific wild-type Th17 cells,
MOG35-55-specific IKKi-deficient Th17 cells induced less severe
EAE with a delayed onset of disease in recipient mice (Fig-
ure 7B). Consistent with the clinical scores, infiltrating CD45+,
CD4+, CD11b+, and Gr-1+ cells were reduced in the brains of
mice in which Ikbke/ MOG-specific Th17 cells were trans-
ferred compared to those that received wild-type MOG-specific
Th17 cells (Figure 7C). Because our results showed that IKKi-
mediated AKT-mTOR activation in Th17 cells requires the
removal of the inhibitory effector of GSK3a on AKT, we also
examined the effect of GSK3a deficiency on IL-1-induced
Th17 cell maintenance and expansion in vivo and Th17 cell
effector function in EAE model. We transferred MOG-specific
Th17 cells from WT and CD4CreGsk3afl/fl mice to sublethally
irradiated Il1r/ mice, followed by 7 days of injection of either
PBS or IL-1b. GSK3a deficiency enhanced the impact of IL-1
on MOG-specific Th17 cells (Figure 7D). The functionality of
MOG-specific Th17 cell from WT and Gsk3a/ mice was
also compared by adoptive transfer to WT recipient mice to
induce EAE. Adoptive transfer of MOG35-55-specific Gsk3a
/
Th17 cells induced more severe EAE in recipient mice
compared to WT Th17 cells (Figures 7E and 7F). Thus,
GSK3a deficiency enhanced Th17 effector cell function in vivo,
leading to increased severity of EAE. Taken together, these
data imply that the IL-1-induced IKKi-GSK3a-mediated AKT-
mTOR axis is critical for the modulation of Th17 effector cell
function in vivo, impacting Th17 cell-dependent EAE
pathogenesis.mmunity 37, 800–812, November 16, 2012 ª2012 Elsevier Inc. 805
Figure 4. IL-1 Induces IKKi Activation to Mediate GSK3a Phosphorylation
(A) Lysates from 293-IL-1R cells untreated or treated for 15 or 30 min with IL-1 (1 ng/ml) were immunoprecipitated with anti-GSK3a, anti-GSK3b, and anti-IKKi,
followed by protein blot analysis with anti-GSK3a, anti-GSK3b, anti-IKKi. WCL, whole cell lysates.
(B) Cell lysates fromwild-type and Ikbke/ Th17 cells untreated or treated with IL-1 (10 ng/ml) for different time points were analyzed by protein blot analysis with
antibodies as indicated.
(C) Lysates from 293-IL-1R cells untreated (0) or treated for 15 or 30 min with IL-1 (1 ng/ml) were immunoprecipitated with anti-GSK3a, anti-GSK3b, anti-TRAF6,
and anti-TAK1 and analyzed by immunoblot with anti-GSK3a, anti-GSK3b, anti-TRAF6, anti-TAK1, and anti-IKKi.
(D) The lysates of kidney epithelial cells from wild-type, Irak4/, and Ikbke/ mice or cell lysates from wild-type, Traf6/, and Tak1/ MEFs were immuno-
precipitated with IKKi antibody, followed by in vitro kinase reaction.
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Figure 5. IKKi-Mediated Inactivation of GSK3a Is Required for IL-1-Induced AKT-mTOR Activation
(A) Cell lysates fromwild-type andGsk3a21A/21A Th17 cells untreated or treated with IL-1 (10 ng/ml) for different time points were analyzed by protein blot analysis
with antibodies as indicated.
(B) Wild-type and Gsk3a21A/21A Th17 cells were rested overnight, followed by incubation with 10 ng/ml IL-1 or IL-2 for 3 additional days. The treated cells were
incubated 1 additional day with 3H for thymidine incorporation experiment.
(C) Naive wild-type,Gsk3a21A/21A CD4+ T cells were polarized to Th17 cells in the presence and absence of IL-1b, followed by intracellular cytokine staining for IL-
17 and IFN-g.
(D) Real-time PCR analysis of relative expression of IL-17, IL-21, IL-23R, and RORgt in wild-type and Gsk3a21A/21A Th17 cells as compared to the Th0 cells.
All data are representative of at least three separate experiments. Error bars in (B) and (D) indicate SD; **p < 0.01 (two-tailed t test).
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This study demonstrates a distinct role of GSK3a versus GSK3b
in IL-1 signaling, which has a critical regulatory role in Th17 cell(E) The cell lysates from 293-IL-1R cells were immunoprecipitated with GSK3a
presence of recombinant IKKi protein.
(F) Recombinant GSK3a and GSK3b proteins were incubated in kinase reaction
(G) Tandem mass spectrometry (ms2) of precursor ions in the GSK3a phosp
SASGPGGTGGGK). All data are representative of at least three separate experim
Imaintenance and/or proliferation. It is important to note that
whereas PI3K and AKT are known to be upstream kinases for
insulin-induced GSK3 phosphorylation and inactivation, we
found here that GSK3a forms a constitutive complex to suppressor GSK3b antibody followed by in vitro kinase reaction in the absence and
in the presence and absence of recombinant IKKi protein.
hopeptide (amino acids 19–50; sequence TSpSFAEPGGGGGGGGGGPGG
ents.
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Figure 6. IKKi Deficiency Leads to Loss of IL-1-Induced AKT-mTOR Activation
(A) Cell lysates from wild-type and Ikbke/ Th17 cells untreated or treated with IL-1 (10 ng/ml) for different time points were analyzed by protein blots with
antibodies as indicated.
(B) Wild-type and Ikbke/ Th17 cells were rested overnight, followed by incubation with 10 ng/ml IL-1 or IL-2 for 3 additional days. The treated cells were
incubated for 1 additional day with 3H for thymidine incorporation experiment.
(C) Naive wild-type and Ikbke/ CD4+ T cells (CD4+CD44lo) were polarized to Th17 cells in the presence and absence of IL-1b, followed by intracellular cytokine
staining for IL-17 and IFN-g.
(D) Real-time PCR analysis of relative expression of IL-17, IL-21, IL-23R, and RORgt in wild-type and Ikbke/ Th17 cells as compared to that in Th0 cells.
Data in (A)–(D) are representative of at least three separate experiments. Error bars in (B) and (D) indicate SEM; **p < 0.01 (two-tailed t test).
(E) Recombinant IKKi and AKT1 proteins were incubated in the in vitro kinase reaction.
(F) Cell lysates from wild-type and Pdpk1/ DLD1 cells untreated or treated with IL-1 (10 ng/ml) for different time points were analyzed by protein blots with
antibodies as indicated.
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Figure 7. IKKi-GSK3a Axis Is Required for IL-1-Mediated In Vivo Th17 Cell Expansion and Survival
(A and D) WT, Gsk3a/, and Ikbke/ MOG-specific Th17 cells were transferred to Il1r/ mice. After 7 days of PBS or IL-1b injection, MOG-specific IL-17-
producing cells in the spleen were detected by ELISPOT.
(B and E) Primed MOG35-55-specific wild-type, Gsk3a
/, and Ikbke/ T cells (10 days) were restimulated with MOG35-55 in vitro in the presence of recombinant
IL-23 for 4 days and then transferred to naive wild-type mice. Graph represents the average clinical score after T cell transfer. n = 5; **p < 0.01 (ANOVA).
(C and F) Immune cell infiltration in the brains of wild-type mice transferred with wild-type, Gsk3a/, and Ikbke/ Th17 cells was analyzed by flow cytometry
(n = 5, 7 days after disease onset).
Error bars (A, C, D, and F) indicate SD; *p < 0.05; **p < 0.01 (two-tailed t test). All data are representative of three independent experiments.
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GSK3a to AKT can take place to impact mTOR activation,
whereas previous studies demonstrated how GSK3b can
reversely act on mTOR activation by meditating the phosphory-
lation of TSC2 (Inoki et al., 2006;Wu and Pan, 2010). These path-
ways probably serve as important links between inflammatory
pathways and cell metabolism. Although we have reported the
importance of IKKi in IL-17-mediated mRNA stabilization (Bulek
et al., 2011), the study here showed that IKKi has a critical role
in Th17 cell maintenance and/or proliferation through the GSK-
AKT-mTOR pathway, which will have an important impact on
the rationale and feasibility for IKKi to be a therapeutic target.
It is well known that insulin receptor signaling results in the
activation of PI3K pathway and subsequent phosphorylation of
GSK3a (S21) and GSK3b (S9) by AKT, leading to inactivation of
GSK3 activity and removal of its inhibitory effect on glycogen
synthase (Cross et al., 1994, 1995, 1997). Therefore, it has
been generally accepted that GSK3 is a downstream substrateIof AKT. Our results unexpectedly showed that both PI3K and
AKT inhibitors failed to inhibit IL-1-induced GSK3a phosphoryla-
tion, although they partially inhibited GSK3b phosphorylation.
GSK3a and GSK3b, encoded by different genes (Woodgett,
1990), seem to be functionally redundant in some signaling
pathways (Doble et al., 2007), although most of the previous
studies have focused on GSK3b. An important finding in this
study is the identification of the constitutive interaction of
GSK3a (but not GSK3b) with AKT, which allowsGSK3a to specif-
ically phosphorylate AKT at T312 to suppress AKT activation and
function. Although GSK3a and GSK3b share nearly identical
sequences in their kinase domains, a glycine-rich extension at
the N terminus of GSK3a accounts for the molecular weight
differences between GSK3a (51 kDa) and GSK3b (47 kDa)
(Woodgett, 1990). The last 76 amino acids within the C terminus
region of GSK3a and GSK3b exhibit only 36% homology (Wood-
gett, 1990). It is likely that these structural differences between
GSK3a and GSK3b contribute to their differential interactionsmmunity 37, 800–812, November 16, 2012 ª2012 Elsevier Inc. 809
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GSK3a, but not GSK3b, with AKT. It is important to note that
when GSK3a was depleted in the supernatant after two cycles
of immunoprecipitation, there was still a substantial amount of
AKT in the supernatant, implying additional AKT complexes in
the cells. It is possible that GSK3a-AKT might be a specific
complex preserved to regulate inflammatory response.
TandemMSshowed that GSK3a phosphorylates AKT at T312,
which is in the substrate binding site according to the structure of
AKT kinase domain. The phosphorylation on the side chain
hydroxyl group of T312 will cause steric clash with the substrate,
thereby inhibiting the AKT kinase activity. Interestingly, whereas
GSK3a deficiency enhanced IL-1-induced phosphorylation of
the activation loop at T308, GSK3a kinase-active knockin
blocked IL-1-induced phosphorylation at T308. Although the
phosphorylation of T308 is essential for AKT activation, the
activation loop does not overlap with the substrate binding
site. Therefore, it is not clear how the phosphorylation at T312
affects the phosphorylation of the activation loop at T308. A
possibility is that the interaction of GSK3awith AKT and/or phos-
phorylation at T312 might interfere with the access of AKT to the
kinase (e.g., PDK1 and/or IKKi, discussed below) for the phos-
phorylation of the activation loop of AKT.
Consistent with the fact that PI3K and AKT inhibitors failed
to inhibit IL-1-induced GSK3a phosphorylation (S21), IKKi defi-
ciency impaired IL-1-induced GSK3a phosphorylation (S21),
implying the possibility of IKKi as the upstream kinase for
GSK3a. In support of this, in vitro kinase assays clearly indicate
that IKKi indeed can directly phosphorylate GSK3a. Interest-
ingly, tandem MS showed that IKKi phosphorylates GSK3a at
S21, suggesting that IKKi is responsible for IL-1-induced
GSK3a phosphorylation at S21. GSK3a S21 is a known inhibitory
phosphorylation site for GSK3a kinase activity, which mainly
blocks the binding of GSK3a to its ‘‘primed substrates’’ (Frame
et al., 2001). Most of the best-described GSK3 substrates
require prephosphorylation at a residue 4 or 5 amino acids (or
further) C-terminal to GSK3 target residue, a phenomenon
referred to as ‘‘priming’’ (Fiol et al., 1987). Although it is unclear
whether AKT is a primed substrate, GSK3a S21 to A21 attenu-
ated IL-1-induced AKT phosphorylation, presumably as a result
of prolonged kinase activity of GSK3a S21A and consequent
inhibitory phosphorylation of AKT at T312. It is interesting to
note that AKT contains several glutamic acid residues (2, 7,
and 10 amino acids) and aspartic acid residues (11 and 13 amino
acids) C-terminal to T312, whichmight serve as priming residues
for the phosphorylation of T312 by GSK3a. Previous studies
have shown that phosphorylation of S21 of GSK3a results in
the N-terminal domain of GSK3 interacting with its phosphate
binding pocket, preventing recognition of primed substrates.
We speculate that IKKi-mediated GSK3a phosphorylation
at S21 might inhibit the recognition of acidic amino acids
C-terminal to T312, thereby blocking AKT T312 phosphorylation
by GSK3a. Future studies are required to test this hypothesis.
IKKi can directly mediate AKT phosphorylation and activation
in response to EGF stimulation (Xie et al., 2011; Guo et al., 2011).
In addition to IKKi’s role in removal of the inhibition of GSK3a on
AKT, an important question is whether IKKi is the direct kinase
for AKT phosphorylation and activation in response to IL-1 stim-
ulation. We found that recombinant IKKi was able to effectively810 Immunity 37, 800–812, November 16, 2012 ª2012 Elsevier Inc.phosphorylate AKT in vitro, indicating that the IKKi probably is
able to directly phosphorylate AKT. However, because PI3K
signaling is required for IL-1-induced AKT-mTOR activation, it
is possible that PDK1 might also be involved in IL-1-induced
AKT phosphorylation and activation. It is well known that PI3K
phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2)
to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3).
Whereas AKT and PDK1 bind to PIP3 at the plasma membrane,
PDK1 phosphorylates the activation loop of AKT at T308 (Alessi
et al., 1997). Interestingly, our results showed that IL-1-induced
phosphorylation of AKT T308 and downstream components of
mTOR (p70S6K, S6, and 4EBP1) were abolished in the absence
of PDK1. These results suggest that whereas IKKi is necessary
for the phosphorylation of GSK3a at S21 to remove the inhibitory
effect of GSK3a on AKT (T312), PDK1 might be the direct kinase
responsible for AKT phosphorylation at T308. It is important to
point out that PDK1 deficiency did not have much impact on
IL-1-induced AKT phosphoryaltion at S473. Therefore, after the
removal of the inhibitory effect of GSK3a on AKT (T312), IKKi
might directly phosphorylate AKT at S473 (Guo et al., 2011; Xie
et al., 2011).
It is intriguing to note that PI3K and AKT inhibitors did partially
inhibit IL-1-induced GSK3b phosphorylation at S9, which
demonstrates the importance of PI3K-AKT in GSK3b phosphor-
ylation. It is plausible that the activated AKT through the action
of IKKi-GSK3a in turn mediates the phosphorylation and inacti-
vation of GSK3b (S9). Consistently, GSK3b was not detected
in the IKKi complex and IKKi can only weakly phosphorylate
GSK3b in vitro. As a matter of fact, previous studies have shown
that because GSK3b inhibits mTOR activation through phos-
phorylation of TSC2 (Inoki et al., 2006), AKT-mediated GSK3b
phosphorylation at S9 should alleviate the inhibitory effect of
GSK3b on mTOR, contributing to mTOR activation. It is impor-
tant to note that although IKKi is unable to phosphorylate
GSK3b in vitro, IKKi deficiency abolished IL-1-induced GSK3b
phopshorylation in Th17 cells. It remains unclear whether there
is another kinase that mediates IL-1-induced GSK3b phosphor-
ylation, because AKT inhibitor only partially blocked IL-1-
induced GSK3b phosphorylation. Future studies are required
to identify the candidate kinase(s) that participate(s) in IL-1-
induced GSK3b phosphorylation.
Although it is well established that AKT phosphorylates and
inactivates GSK3a and GSK3b (e.g., in insulin signaling), we
showed that GSK3a can reversely phosphorylate AKT and
suppress AKT activation in resting cells and that IL-1 stimulation
activates IKKi to phosphorylate GSK3a, resulting in inactivation
of GSK3a to promote AKT-mTOR activation. This study has
been mainly carried out in Th17 cells, demonstrating the critical
role of the IKKi-GSK3a-AKT-mTOR axis in IL-1-dependent Th17
cell maintenance and/or proliferation and function. The kinase
mTOR has emerged as an important regulator of the differentia-
tion of helper T cells (Delgoffe et al., 2009, 2011). The mTOR
complex promotes phosphorylation of the translational regula-
tors S6K1 and 4E-BP1 and is believed to have a central role in
regulating cellular growth and proliferation by modulating
metabolism. In addition to the impact of mTOR-mediated
4E-BP1 on the translation of cell cycle regulators cMyc and
Cyclin D1, recent studies indicate that mTOR activation is
required for HIF1a induction, a transcription factor driving the
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aerobic glycolysis has been associated with lymphocyte pro-
liferation, HIF1a-dependent glycolytic pathway plays a critical
role in Th17 cell differentiation. We found that IL-1 stimulation
also strongly induced HIF1a expression in differentiated Th17
cells, which is specially blocked by rapamycin (data not shown).
Future studies are required to elucidate how IL-1-induced
mTOR activation leads to Th17 cell proliferation and effector
function.
EXPERIMENTAL PROCEDURES
Mice
Wild-type mice were purchased from Taconic Laboratories. Il1r/ mice were
purchased from Jackson Laboratories. Gsk3a/ mice, Gsk3afl/fl mice, and
Gsk3a21A/21A mice were generated as described (MacAulay et al., 2007; Doble
et al., 2007; McManus et al., 2005). Mice were housed in the animal facility
(SPF condition) at the Cleveland Clinic Foundation in compliance with the
guidelines set by Institutional Animal Care and Use Committee.
T Cell Differentiation
Naive CD4+CD44lo T cells from wild-type C57BL/6, CD4CreGsk3afl/fl, and
Gsk3a21A/21A mice were sorted by flow cytometry and activated with plate-
bound 3 mg/ml anti-CD3 and 3 mg/ml anti-CD28 and in the presence of
5 ng/ml TGF-b (Peprotech), 10 ng/ml IL-6 (Peprotech), 5 mg/ml anti-IL-4
(11B11), 5 mg/ml anti-IFN-g (XMG 1.2), 10 ng/ml IL-1b (R&D System), or
combination of these stimuli. For intracellular staining, cells were stimulated
with PMA and ionomycin in the presence of Golgi-stop for 4 hr, after which
IL-17- and IFN-g-producing cells were analyzed with intracellular staining.
Proliferation
Th17 cells were cultured (20 3 103 cells/well) at a final volume of 200 ml/well
in 96-well plates. In some wells, rapamaycin (50 nM) (Sigma) was added.
After incubation for 96 hr, wells were pulsed with [methyl-3H]thymidine
(1.0 mCi/well, specific activity 6.7 Ci/mM; New England Nuclear) and harvested
16 hr later by aspiration onto glass fiber filters. For proliferation assay, levels of
incorporated radioactivity were determined by scintillation spectrometry.
Quantitative Real-Time RT-PCR
Expression of the genes encoding IL-17A, IL-23R, IL-21, and RORgt were
quantified with the SYBER Green PCR Master Mix kit (Applied Biosystems)
with primer pairs selected for amplification of each individual cytokine (Gulen
et al., 2010). Relative gene expression was determined as the ratio of cytokine
to b-actin gene expression levels for each sample.
EAE Induction
Mice were immunized with MOG35–55 plus complete Freund’s adjuvant in
conditions that induce active EAE. Th17 cells from lymph nodes of the immu-
nized mice were restimulated with MOG35–55 (20 mg/ml) and IL-23 (20 ng/ml)
as described before (Gulen et al., 2010). After 4 days of culture, cells were
collected and injected into recipient WT mice that had been sublethally irradi-
ated (600 rads) at 4 hr before injection. Although 2 3 107 total WT cells were
transferred to each mouse, the numbers of Gsk3a/ and Ikbke/ cells trans-
ferred were normalized against WT based on the ELISPOT analysis of the
MOG-specific Th17 cell numbers after the cell culture (Figure S4). For the
detection of IL-1b effect on the MOG-specific Th17 cells, cells were injected
intravenously into irradiated (600 rads) Il1r/mice. The mice were intraperito-
neally injected daily either with PBS or 400 ng IL-1b (R&D) for 7 days. After
7 days, ELISPOT analysis was performed for the MOG-specific IL-17-
producing cells from spleens of Il1r/ mice with mouse IL-17 ELISPOT kit
(R&D) according to manufacturer instructions.
Transfection, Coimmunoprecipitations, and Immunoblots
Procedures for transfection, coimmunoprecipitations, and immunoblots with
293 cells were previously described (Yao et al., 2007). Antibodies used in
this study include primary anti-AKT, GSK3a/b (Santa Cruz), GSK3a, GSK3b,Ip-GSK3a/b, p-AKT, p-4EBP1, 4EBP1, p-70S6K, p-IkBa, p-JNK, p-mTOR,
mTOR, p-S6, p-TSC2, TSC2, PI3K, IKKi (Cell Signaling), andGAPDH (Ambion).
In Vitro Kinase Assay
Recombinant proteins (GST-GSK3a [CellSciences], GST-GSK3b [R&D], and
GST-IKKi/IKKE [Active Motif]) or immunoprecipitated beads were subjected
to in vitro kinase reaction as previously described (Bulek et al., 2011).
Trypsin Digestion, LC/ESI-MS/MS, and MS Data Analysis
The detailed methods for Trypsin digestion and LC/ESI-MS/MS have been
previously described (Pang et al., 2002; Gao et al., 2004). MS/MS data were
searched against human database by Sequest through Sorcerer (Sage-N
Research, Milpitas, CA). The searched data set was processed by TPP
(Trans-Proteomics Pipeline) and filtered with Peptide Prophet (Keller et al.,
2002) as well as Sorcerer Sequest scores (Xcorr > 2.0, DelCN > 0.095,
Rsp < 5) (Pang et al., 2002; Gao et al., 2004). Additionally, the phospho-
peptides that passed the filtering criteria were manually inspected to confirm
the assignments generated by the data searching algorithm.
Statistics
ANOVA was used for EAE clinical score studies. The Student’s t test was used
to assess all other statistical values. p values were determined and error bars
represent standard error of the mean (SEM).
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